Find a Trial

Trial Summary

Protocol No.OTHN-CC-IUSCCC-0756
Principal InvestigatorSim, Michael
PhasePhase II
Age GroupAdult
TitleAdjuvant Treatment Deintensification after Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
DescriptionOropharyngeal squamous cell carcinoma (OPSCC), commonly known as throat cancer or tonsil cancer, has seen a dramatic rise in incidence over the last twenty years. There are two types of OPSCC: human papillomavirus-positive (HPV+) and human papillomavirus-negative (HPV-). People with OPSCC, regardless of their type, typically receive standard treatment with a combination of chemotherapy, radiation therapy, and surgery. Due to the intensity of standard treatment, survivors may experience unwanted long-term side effects. The goal of this research study is to see if intensifying (stopping or scaling back) treatment still provides the same, or perhaps even better, results when compared to standard treatment.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Primary tumor of the oropharynx (palatine tonsil, tongue base, soft palate, lateral or posterior walls of oropharynx).
  • Histopathologically confirmed squamous cell carcinoma.
  • HPV+ tumor, as determined by p16, in-situ hybridization, or real-time polymerase chain reaction.
For a full list of participation criteria, please visit
Applicable Disease SitesEsophagus
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632